China's License-Out Boom – $110 Billion and 81 Deals in H1 2026

I. Introduction: A Historic Licensing Boom

In the first half of 2026, China's biopharmaceutical industry achieved a record-breaking milestone: 81 out-licensing deals with a total transaction value of approximately $110 billion — already reaching 80% of the full-year 2025 total. The total upfront payments exceeded $5 billion, accounting for approximately 70% of the full-year 2025 total.

Perhaps most remarkably, 8 of the global Top 10 biopharma licensing deals in H1 2026 originated from Chinese sellers — a clear signal that China has become the world's primary source of innovative drug assets.

II. The Top 5 Mega-Deals of 2026

1. CSPC × AstraZeneca – $18.5 Billion

CSPC Pharmaceutical Group (石药集团) and AstraZeneca signed the largest licensing deal of 2026 — a collaboration valued at $18.5 billion for a portfolio of 8 innovative long-acting peptide drugs. The deal covers multiple therapeutic areas, including cardiovascular, metabolic, and renal diseases.

Significance: This deal demonstrates global confidence in China's peptide drug development platform and positions CSPC as a major player in the long-acting peptide space.

2. Hengrui × BMS – $15.2 Billion

Jiangsu Hengrui Medicine (恒瑞医药) and Bristol-Myers Squibb entered into a licensing agreement valued at $15.2 billion for 13 early-stage oncology, hematology, and immunology assets. This was one of the largest oncology-focused licensing deals of the year.

Significance: Hengrui, long known as China's "R&D powerhouse," has now validated its discovery platform with one of the world's leading oncology companies. The deal covers both clinical-stage and preclinical assets, reflecting BMS's confidence in Hengrui's early-stage pipeline.

3. Innovent × Pfizer – $10.5 Billion

Innovent Biologics (信达生物) and Pfizer signed a collaboration valued at $10.5 billion for 12 oncology assets. The deal includes both PD-1 combination studies and novel immuno-oncology targets.

Significance: Pfizer's decision to license multiple assets from Innovent — a company it has collaborated with since 2015 — validates the maturity of Innovent's research capabilities and its position as one of China's leading biotech platforms.

4. Multiple Companies × MNCs – $5–6 Billion Tier

Several additional deals in the $5–6 billion range were announced, including:

• Akeso × undisclosed partner — multiple bispecific antibodies
• Simcere × Sanofi — CNS and oncology assets
• Zai Lab × Novartis — anti-infective and oncology programs

5. Sino Biopharm × Cipla – $123 Million

While smaller in absolute value, the Sino Biopharmaceutical (中国生物制药) × Cipla deal is significant for its regional scope. The agreement grants Cipla rights to TQB2102, a HER2 bispecific ADC, in India, South Africa, and five other emerging markets — representing a "Chinese R&D + Local Commercialization" model for emerging markets.

III. The Full Picture: 81 Deals, 20 Countries

The 81 out-licensing deals completed in H1 2026 covered a wide range of therapeutic areas and involved partners from 20 countries and territories, including:

• United States — the largest destination for Chinese licenses
• United Kingdom — AstraZeneca, GSK, and others
• France — Sanofi and other European pharma
• Germany — Bayer, Merck KGaA
• Japan — Takeda, Daiichi Sankyo
• Switzerland — Novartis, Roche
• India — Cipla and other emerging market partners

Deal Characteristics

Characteristic	H1 2026 Data
Total deals	81
Total transaction value	~$110 billion
Total upfront payments	~$5 billion
Average deal size	~$1.36 billion
Top therapeutic area	Oncology (60%+ of deals)
Second most active	Metabolic diseases
Emerging areas	CNS, immunology, anti-infectives

IV. Why Chinese Assets Are in High Demand

1. Quality and Validation

Chinese drug candidates are increasingly supported by global-standard clinical data — randomized, double-blind, controlled trials that meet ICH guidelines. The adoption of ICH standards has made Chinese data acceptable to U.S. FDA and EMA reviewers.

2. Speed and Efficiency

Chinese companies have demonstrated remarkable speed in clinical development, thanks to:

• Fast trial enrollment — China's large patient population enables rapid recruitment
• Regulatory efficiency — IND 30-day silent approval accelerates trial initiation
• Competitive costs — Clinical trial costs in China are 40–60% lower than in the U.S.

3. Novel Mechanisms and First-in-Class Assets

Chinese companies are no longer developing "me-too" drugs. In 2026, a significant portion of licensed assets were:

• First-in-class — novel mechanisms not previously validated in humans
• Best-in-class — improved versions of existing mechanisms with superior profiles
• Novel modalities — ADCs, bispecifics, CAR-T, PROTACs, and RNA therapeutics

4. Strategic Partnerships and Track Record

Major MNCs have established long-term partnerships with Chinese companies based on successful track records:

• BMS — continuing its partnership with SystImmune (BL-B01D1)
• MSD — expanding its collaboration with Kelun-Biotech (SKB264 and others)
• BioNTech — deepening its relationship with MediLink (YL202)
• Roche — licensing CLDN18.2 CAR-T from CARsgen

V. The Evolution: From "Selling Molecules" to "Selling Systems"

The 2026 out-licensing boom represents a qualitative shift in China's biopharma innovation model.

• Before 2020: China was primarily a source of single-asset licenses — MNCs licensed one or two molecules from Chinese biotechs.
• 2020–2024: China became a source of portfolio-level deals — MNCs licensed multiple assets from a single Chinese partner.
• 2025–2026: China is now a source of platform-level collaborations — MNCs are investing in Chinese R&D platforms, not just individual assets.

As one industry observer noted: "China has moved from selling molecules to selling systems."

VI. What This Means for International Patients

The license-out boom has direct implications for patients worldwide:

• Faster global access: Drugs developed in China are now being commercialized by global pharma companies, meaning patients worldwide can access them sooner.
• Quality validation: When a major MNC licenses a Chinese asset, it validates the quality of Chinese R&D and manufacturing.
• Competitive pricing: The same Chinese-developed therapies, when approved globally, are often priced more competitively than U.S.-developed alternatives.
• More treatment options: The flow of Chinese innovation into global pipelines expands the number of treatment options available to patients.

VII. Conclusion: A Sustainable Model

The 2026 out-licensing boom is not a one-time event. It reflects a fundamental transformation of China's biopharmaceutical industry — from a follower to a global leader in drug discovery and development.

With 81 deals in H1 2026 and a pipeline of over 4,700 Chinese-origin drug candidates in global R&D, the licensing boom is likely to continue and accelerate.

China's innovative drug industry is no longer just a source of assets — it is a global innovation engine.